drugset / Trial / NCT04204161
A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma
Phase 1
Unknown
30 enrolled
Shenzhen BinDeBio Ltd.
Xiangya Hospital of Central South University · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, open-label, uni-center, phase I study . In this study, Children withCD19+/CD22+ R/R B-cell acute lymphoblastic leukemia or lymphoma will be treated with CAR-T19/CAR-T22 Immunotherapy to determine the safety and efficacy of treatment.
Timeline
- Start
- 2019-10-08
- Primary completion
- 2021-10-30
- Completion
- 2024-10-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tisagenlecleucel | Cell therapy | 100000 cells/kg | Intravenous |
| Subject | Tisagenlecleucel | Cell therapy | 2.5e+08 cells/kg | Intravenous |